ATXS - Astria Corp Total Debt to Capital

Astria Therapeutics (ATXS) develops drugs for the therapy of rare immune system failures. The current stock quotes visualized below for the debt-to-equity metric stand at 0.02. The company is currently in the product testing phase, maintaining modest revenue and anticipating cash flow following licensing. High R&D expenses preclude operating leverage, meaning profit growth is only possible after the commercialization of its product lines.

This indicator determines the degree of financial leverage by comparing total liabilities to the business's own funds. The history of changes in the total debt-to-equity ratio reflects the dynamics of the company's dependence on borrowed financing relative to the market value of net assets. The metric is calculated as the ratio of all creditor claims to equity, measuring bankruptcy risk. For Astria Therapeutics (ATXS), a low debt load confirms the stability of the model. This allows the company to rely on its scientific authority and successful clinical trials without pressure from creditors.